Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-25 @ 2:16 AM
NCT ID:
NCT06335160
Brief Summary:
To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine
Detailed Description:
A randomized, controlled, and parallel study will comprise 46 patients with UC. Patients will be recruited from GastroEnterology Department, Mansoura University Hospital.
The participants will be randomly assigned into two groups as follow:
Group 1: control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
Group 2: (mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months.
Study:
NCT06335160
Study Brief:
Protocol Section:
NCT06335160